Targeted lipid based drug conjugates: A novel strategy for drug delivery

被引:40
|
作者
Vadlapudi, Aswani Dutt [1 ]
Vadlapatla, Ramya Krishna [1 ]
Kwatra, Deep [2 ]
Earla, Ravinder [1 ]
Samanta, Swapan K. [1 ]
Pal, Dhananjay [1 ]
Mitra, Ashim K. [1 ]
机构
[1] Univ Missouri, Sch Pharm, Div Pharmaceut Sci, Kansas City, MO 64108 USA
[2] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA
关键词
Acyclovir; Targeted lipid prodrugs; Biotin; SMVT; Affinity; Drug delivery; DEPENDENT MULTIVITAMIN TRANSPORTER; L-VALYL ESTER; ACYCLOVIR DIPHOSPHATE DIMYRISTOYLGLYCEROL; POSSIBLE ANTIVIRAL AGENTS; CORNEAL EPITHELIAL-CELLS; AMINO-ACID TRANSPORTER; FUNCTIONAL-CHARACTERIZATION; OLIGOPEPTIDE TRANSPORTER; BIOTIN UPTAKE; DIPEPTIDE PRODRUGS;
D O I
10.1016/j.ijpharm.2012.05.033
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A majority of studies involving prodrugs are directed to overcome low bioavailability of the parent drug. The aim of this study is to increase the bioavailability of acyclovir (ACV) by designing a novel prodrug delivery system which is more lipophilic, and at the same time site specific. In this study, a lipid raft has been conjugated to the parent drug molecule to impart lipophilicity. Simultaneously a targeting moiety that can be recognized by a specific transporter/receptor in the cell membrane has also been tethered to the other terminal of lipid raft. Targeted lipid prodrugs i.e., biotin-ricinoleicacid-acyclovir (B-R-ACV) and biotin-12hydroxystearicacid-acyclovir (B-12HS-ACV) were synthesized with ricinoleicacid and 12hydroxystearicacid as the lipophilic rafts and biotin as the targeting moiety. Biotin-ACV (B-ACV), ricinoleicacid-ACV (R-ACV) and 12hydroxystearicacid-ACV (12HS-ACV) were also synthesized to delineate the individual effects of the targeting and the lipid moieties. Cellular accumulation studies were performed in confluent MDCK-MDR1 and Caco-2 cells. The targeted lipid prodrugs B-R-ACV and B-12HS-ACV exhibited much higher cellular accumulation than B-ACV, R-ACV and 12HS-ACV in both cell lines. This result indicates that both the targeting and the lipid moiety act synergistically toward cellular uptake. The biotin conjugated prodrugs caused a decrease in the uptake of [H-3] biotin suggesting the role of sodium dependent multivitamin transporter (SMVT) in uptake. The affinity of these targeted lipid prodrugs toward SMVT was studied in MDCK-MDR1 cells. Both the targeted lipid prodrugs B-R-ACV (20.25 +/- 1.74 mu M) and B-12HS-ACV (23.99 +/- 3.20 mu M) demonstrated higher affinity towards SMVT than B-ACV (30.90 +/- 4.19 mu M). Further, dose dependent studies revealed a concentration dependent inhibitory effect on [H-3] biotin uptake in the presence of biotinylated prodrugs. Transepithelial transport studies showed lowering of [H-3] biotin permeability in the presence of biotin and biotinylated prodrugs, further indicating a carrier mediated translocation by SMVT. Overall, results from these studies clearly suggest that these biotinylated lipid prodrugs of ACV possess enhanced affinity towards SMVT. These prodrugs appear to be potential candidates for the treatment of oral and ocular herpes virus infections, because of higher expression of SMVT on intestinal and corneal epithelial cells. In conclusion we hypothesize that our novel prodrug design strategy may help in higher absorption of hydrophilic parent drug. Moreover, this novel prodrug design can result in higher cell permeability of hydrophilic therapeutics such as genes, siRNA, antisense RNA, DNA, oligonucleotides, peptides and proteins. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:315 / 324
页数:10
相关论文
共 50 条
  • [21] Novel liposaccharide conjugates for drug and peptide delivery
    Drouillat, B
    Hillery, AM
    Dekany, G
    Falconer, R
    Wright, K
    Toth, I
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (01) : 25 - 30
  • [22] Editorial: The magic bullet evolution in tumor therapy: novel drug conjugates for targeted delivery
    Gazzola, Silvia
    Neundorf, Ines
    Sewald, Norbert
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [23] Novel advances in targeted drug delivery
    Ozturk-Atar, Kivilcim
    Eroglu, Hakan
    Calis, Sema
    JOURNAL OF DRUG TARGETING, 2018, 26 (08) : 633 - 642
  • [24] Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment
    Zhuang, Chunlin
    Guan, Xianghong
    Ma, Hao
    Cong, Hui
    Zhang, Wannian
    Miao, Zhenyuan
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 163 : 883 - 895
  • [25] Stimuli-Responsive Aptamer-Drug Conjugates for Targeted Drug Delivery and Controlled Drug Release
    Zhu, Shanshan
    Gao, Huan
    Li, Wenyuan
    He, Xiaocong
    Jiang, Panpan
    Xu, Feng
    Jin, Guorui
    Guo, Hui
    ADVANCED HEALTHCARE MATERIALS, 2024, 13 (23)
  • [26] Conjugates of Cryptophycin and RGD or isoDGR Peptidomimetics for Targeted Drug Delivery
    Borbely, Adina
    Figueras, Eduard
    Martins, Ana
    Bodero, Lizeth
    Dias, Andre Raposo Moreira
    Rivas, Paula Lopez
    Pina, Arianna
    Arosio, Daniela
    Gallinari, Paola
    Frese, Marcel
    Steinkuehler, Christian
    Gennari, Cesare
    Piarulli, Umberto
    Sewald, Norbert
    CHEMISTRYOPEN, 2019, 8 (06) : 737 - 742
  • [27] Multidrug multiligand conjugates (MDMLCs) for targeted drug delivery.
    Safavy, A
    Raisch, KP
    Bonner, JA
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3744S - 3744S
  • [28] Design and synthesis of functionalized cellulose nanocrystals-based drug conjugates for colon-targeted drug delivery
    Lirong Tang
    Fengcai Lin
    Tao Li
    Zhenghan Cai
    Biyun Hong
    Biao Huang
    Cellulose, 2018, 25 : 4525 - 4536
  • [29] Targeted delivery for regenerative medicines: an untapped opportunity for drug conjugates
    Valeur, Eric
    Knerr, Laurent
    Olwegard-Halvarsson, Maria
    Lemurell, Malin
    DRUG DISCOVERY TODAY, 2017, 22 (06) : 841 - 847
  • [30] Antibody-drug conjugates: targeted delivery and future prospects
    Lambert, John M.
    THERAPEUTIC DELIVERY, 2016, 7 (05) : 279 - 282